



Abbott

J.P. Morgan Healthcare Conference

January 9, 2024

Robert Ford, Chairman and Chief Executive Officer

FORWARD LOOKING STATEMENT

Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2022, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Abbott is reimagining innovation for a better, healthier world

CREATING LIFE-CHANGING TECHNOLOGIES THAT
ARE BOTH **ACCESSIBLE AND AFFORDABLE**

HELPING MORE PEOPLE IN MORE PLACES
LIVE HEALTHIER AND FULLER LIVES

CREATING A HEALTHIER, **MORE SUSTAINABLE
WORLD AND COMPANY**

Our goal is to help improve the lives of one in
every three people on the planet by 2030



Abbott at a glance

115,000

PEOPLE

136

YEARS IN BUSINESS

160+

COUNTRIES

\$43.7B

2022 SALES

TRUSTED PRODUCTS

FreeStyle Libre 

MitraClip™

Similac®

Alinity

Ensure®

pediasure®

Duphaston®
Hydrogesterone

BinaxNOW™

Pedialyte®

Eterna™
SCS System

BurstDR™
Stimulation 

Xience™


BRUFEN

AVEIR™ VR
Leadless Pacemaker


Products may not be available in all markets.

Abbott has a proven framework for achieving sustainable long-term growth and value creation


PORTFOLIO BALANCE



GEOGRAPHIC BALANCE




PAYER BALANCE



Charts based on YTD 3Q23 results

Building strong momentum



* Excludes COVID-19 testing-related sales


Attractive pipeline to sustain top tier growth

CURRENT GROWTH CONTRIBUTORS

- FreeStyle Libre 3[®] Continuous Glucose Monitor
- Alinity[®] Suite of Diagnostics Systems/Automation
- MitraClip[™] Transcatheter Mitral Valve Repair
- TriClip[™] Transcatheter Tricuspid Valve Repair
- Aveir[™] Leadless Pacemaker
- Navitor[™] Transcatheter Aortic Valve Replacement
- Amulet[™] Left Atrial Appendage Closure
- CardioMEMS[™] Heart Failure Remote Monitoring System



TriClip[™]



FreeStyle Libre[®]




Aveir[™]

FUTURE GROWTH CONTRIBUTORS

- Lingo[™] Consumer biowearable sensors
- TBI Test Point of Care Traumatic Brain Injury Test
- FreeStyle Libre[®] Glucose + Ketone Sensor
- Esprit[™] Below-The-Knee (BTK) Resorbable Stent
- Volt[™] Pulsed Field Ablation (PFA) System
- Protality[™] Nutritional Drink (preserves muscle during weight loss)
- Alinity n[™] Next Generation Diagnostics System
- Biosimilars Portfolio of Biosimilars for Emerging Markets



Volt[™]



Esprit[™]

Well-balanced capital allocation delivers strong shareholder returns



Returning cash to shareholders

>\$17Bn returned in the form of dividends and share repurchases since 2021



Investing for future growth

>\$5Bn in capital expenditures since 2021 to support future growth



Built a fortress balance sheet



The Promise of AI in Healthcare

Uses of AI in Healthcare:

- For Diagnosis
- For Treatment
- To Empower Consumers

Abbott is leading the way:

- Technologies that predict cardiac events
- Data and Insights that improve treatment decisions and positively influence lifestyle choices
- Software tools that optimize procedure outcomes





life. to the fullest.®

Abbott